141 related articles for article (PubMed ID: 27479016)
1. Recent advances in epigenomics in NSCLC: real-time detection and therapeutic implications.
Di Paolo A; Del Re M; Petrini I; Altavilla G; Danesi R
Epigenomics; 2016 Aug; 8(8):1151-67. PubMed ID: 27479016
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy.
Ricciuti B; Mencaroni C; Paglialunga L; Paciullo F; Crinò L; Chiari R; Metro G
Med Oncol; 2016 Feb; 33(2):18. PubMed ID: 26786153
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
4. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
[TBL] [Abstract][Full Text] [Related]
5. Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas.
Carvalho RH; Hou J; Haberle V; Aerts J; Grosveld F; Lenhard B; Philipsen S
J Thorac Oncol; 2013 May; 8(5):562-73. PubMed ID: 23524404
[TBL] [Abstract][Full Text] [Related]
6. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.
Luo R; Song J; Xiao X; Xie Z; Zhao Z; Zhang W; Miao S; Tang Y; Ran L
Aging (Albany NY); 2020 Jul; 12(14):14649-14676. PubMed ID: 32723974
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art.
Szejniuk WM; Robles AI; McCulloch T; Falkmer UGI; Røe OD
Pharmacogenomics J; 2019 Feb; 19(1):5-14. PubMed ID: 30190521
[TBL] [Abstract][Full Text] [Related]
9. A panel of promoter methylation markers for invasive and noninvasive early detection of NSCLC using a quantum dots-based FRET approach.
Ma Y; Bai Y; Mao H; Hong Q; Yang D; Zhang H; Liu F; Wu Z; Jin Q; Zhou H; Cao J; Zhao J; Zhong X; Mao H
Biosens Bioelectron; 2016 Nov; 85():641-648. PubMed ID: 27240011
[TBL] [Abstract][Full Text] [Related]
10. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression.
Fang J; Sun CC; Gong C
Biochem Biophys Res Commun; 2016 Sep; 478(2):811-7. PubMed ID: 27501756
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer.
Li W; Wang Y; Zhang Q; Tang L; Liu X; Dai Y; Xiao L; Huang S; Chen L; Guo Z; Lu J; Yuan K
PLoS One; 2015; 10(8):e0134220. PubMed ID: 26237047
[TBL] [Abstract][Full Text] [Related]
13. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictive and prognostic markers in non-small-cell lung cancer.
Coate LE; John T; Tsao MS; Shepherd FA
Lancet Oncol; 2009 Oct; 10(10):1001-10. PubMed ID: 19796752
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer epigenetics and genetics.
Risch A; Plass C
Int J Cancer; 2008 Jul; 123(1):1-7. PubMed ID: 18425819
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer.
Liu S; Chen X; Chen R; Wang J; Zhu G; Jiang J; Wang H; Duan S; Huang J
Oncotarget; 2017 May; 8(22):36354-36367. PubMed ID: 28422739
[TBL] [Abstract][Full Text] [Related]
18. Translating cancer epigenomics into the clinic: focus on lung cancer.
Mari-Alexandre J; Diaz-Lagares A; Villalba M; Juan O; Crujeiras AB; Calvo A; Sandoval J
Transl Res; 2017 Nov; 189():76-92. PubMed ID: 28644958
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnostics in advanced NSCLC: trying to maximize a non-ideal situation.
Lim EH; Tan P
J Thorac Oncol; 2007 Aug; 2(8):782. PubMed ID: 17762350
[No Abstract] [Full Text] [Related]
20. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer.
Jiang LP; Zhu ZT; He CY
Future Oncol; 2016 May; 12(9):1105-15. PubMed ID: 27033050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
